Articles by Katie Anderson

1. Innovation, Growth (and Happiness) Projected for Pharma 11/10/2025

   Not only is investment increasing in pharma, but innovation is propelling growth in multiple drug segments, and the people supporting this growth and innovation remain happy.

2. Shaping The Future Of GLP-1 Quality 11/4/2025

   Three experts—Doug Bakan (CTO of Kailera), Hyung Heon Kim (CEO of MetaVia) and Deepa Nagpal (Founder of SygnifyQ)—joined us on Oct. 15, 2025, to explore this topic, find out the most common quality failures, learn what innovation is occurring and find out what business decisions can help support both quality and quantity.

3. ISPE Awards 8 Innovative Pharma Facilities 10/31/2025

   The Facility of the Year Awards (FOYA) celebrates 20 years of innovation and excellence in 2025, and I had the pleasure of joining the celebration at the 2025 ISPE FOYA Banquet and Awards Celebration on Oct. 26, 2025.

4. 9 Drugs Granted Fast Track By FDA's Voucher Program 10/23/2025

   With targets like pancreatic cancer, deafness, blindness, infertility and vaping addiction, these drugs were chosen due to an unmet need, addressing a public health crisis, boosting domestic manufacturing or increasing affordability.

5. Leaders In The Excipient Market: Region And Type 10/21/2025

   Though North America led the market with a 38.32% market share of $3.15 billion in 2024, Asia Pacific is expected to have the fastest growth in the upcoming years.

6. 3 [Potential] Solutions To A More Resilient Supply Chain 10/16/2025

   In her opening presentation, Harney noted that there were 98 drug shortages in 2024, 40 medicines in shortage for over three years, and the average duration of a shortage has increased from three years to four years.

7. Extreme Weather Is Testing Pharma's Resilience — Is It Ready? 10/14/2025

   It may sound like a stretch, but researchers from Harvard University showed how a disproportionate amount of pharmaceutical manufacturers are in areas of climate-driven extreme weather events. Is the pharmaceutical industry currently set up to withstand them?  

8. Eco-Friendly HBL: Cheaper, Cleaner, And Ready For Pharma 10/6/2025

   Researchers at the University of Maine may have found a way to do two out of three by developing a new method of producing (S)-3-hydroxy-γ-butyrolactone (HBL) for statins, HIV inhibitors and antibiotics that can lower their production cost with an added benefit of reducing their carbon footprint.

9. Roll Call In The Oral GLP-1 Race 9/26/2025

   The market for GLP-1 agonists is booming and expected to only get bigger. As rates for obesity and cardiovascular disease increase, so too does the demand for GLP-1 drugs.

10. Pfizer Strengthens Obesity Foothold With Metsera Acquisition 9/22/2025

    After discouraging efforts to bring two oral obesity drugs to market—danuglipron and lotiglipron—this acquisition launches Pfizer back into the obesity therapeutic game.